12:00 AM
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trobalt retigabine regulatory update

The German Institute for Quality and Efficiency in Healthcare (IQWiG) said adjunctive epilepsy drug Trobalt retigabine from GlaxoSmithKline provides "no additional benefit" over comparators. The agency said GSK's submission contained no evaluable data because the pharma selected different comparators than IQWiG.

IQWiG said the pharma did not take...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >